NASDAQ:BDSI BioDelivery Sciences International (BDSI) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free BDSI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$5.59▼$5.6050-Day Range$5.54▼$5.6052-Week Range$2.50▼$5.62Volume2.09 million shsAverage Volume3.34 million shsMarket Capitalization$577.05 millionP/E Ratio6.74Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get BioDelivery Sciences International alerts: Email Address Ad Porter & CompanyHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.Click here to watch this now before it’s too late. About BioDelivery Sciences International Stock (NASDAQ:BDSI)BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.Read More Ad Porter & CompanyHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.Click here to watch this now before it’s too late. BDSI Stock News HeadlinesSeptember 14, 2023 | usnews.comFlorida International UniversityMay 6, 2023 | usnews.comInternational High School for Health SciencesMay 13, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.October 15, 2022 | omaha.comInternational climate change bodies win humanity awardSeptember 16, 2022 | thestreet.comPerilous Reversal Watch: BioDelivery Sciences International (BDSI)September 13, 2022 | npr.orgScienceMay 10, 2022 | seekingalpha.comCollegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2022 Results - Earnings Call TranscriptMay 2, 2022 | thestreet.comJim Cramer's Top Stock Picks: DF MNST BDSIMay 13, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.April 5, 2022 | benzinga.comWhy Collegium Pharmaceutical's Shares Are Trading Higher TodayFebruary 24, 2022 | finance.yahoo.comCardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue EstimatesFebruary 24, 2022 | seekingalpha.comBioDelivery Sciences launches migraine therapy in U.S.February 24, 2022 | finance.yahoo.comBioDelivery Sciences International (BDSI) Just Flashed Golden Cross Signal: Do You Buy?February 15, 2022 | stockhouse.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioDelivery Sciences International, Inc. BuyoutFebruary 14, 2022 | apnews.comBDSI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of BioDelivery Sciences International, Inc. Is Fair to ShareholdersFebruary 14, 2022 | apnews.comBDSI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of BioDelivery Sciences International, Inc. Is Fair to ShareholdersFebruary 14, 2022 | finance.yahoo.comBioDelivery's stock rockets toward a 2-year high after buyout deal with Collegium at a 54% premiumFebruary 7, 2022 | finance.yahoo.comWhy the Earnings Surprise Streak Could Continue for BioDelivery (BDSI)February 6, 2022 | nasdaq.comBioDelivery Sciences International (NASDAQ:BDSI) Could Easily Take On More DebtJanuary 31, 2022 | finance.yahoo.comShould Value Investors Pick BioDelivery (BDSI) Stock Now?December 28, 2021 | finance.yahoo.comRaleigh pharma gets favorable ruling in case for drug exclusivityDecember 20, 2021 | fool.comWhy BioDelivery Sciences International Stock Was Up 28.5% MondayDecember 3, 2021 | finance.yahoo.comWhy Is BioDelivery (BDSI) Down 20.8% Since Last Earnings Report?November 17, 2021 | finance.yahoo.comBioDelivery Sciences International, Inc. (BDSI)November 15, 2021 | finance.yahoo.comBiodelivery Sciences Intl Insider Makes $320K Stock PurchaseNovember 9, 2021 | nasdaq.comTuesday 11/9 Insider Buying Report: BDSI, BALYNovember 3, 2021 | finance.yahoo.comBioDelivery Sciences International (BDSI) Tops Q3 Earnings EstimatesSee More Headlines Receive BDSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioDelivery Sciences International and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:BDSI CUSIP09060J10 CIK1103021 Webwww.bdsi.com Phone(919) 582-9050Fax919-582-9051Employees200Year Founded1997Profitability EPS (Most Recent Fiscal Year)$0.83 Trailing P/E Ratio6.74 Forward P/E Ratio14.71 P/E GrowthN/ANet Income$84.86 million Net Margins50.90% Pretax Margin17.77% Return on Equity21.25% Return on Assets10.56% Debt Debt-to-Equity Ratio0.29 Current Ratio2.45 Quick Ratio2.17 Sales & Book Value Annual Sales$166.70 million Price / Sales3.46 Cash Flow$0.36 per share Price / Cash Flow15.42 Book Value$1.90 per share Price / Book2.94Miscellaneous Outstanding Shares103,229,000Free Float92,927,000Market Cap$577.05 million OptionableOptionable Beta0.56 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Jeffrey Allen Bailey (Age 59)CEO & Director Comp: $599.96kMr. Scott M. Plesha (Age 57)Pres & Chief Commercial Officer Comp: $629.46kMr. James Vollins J.D. (Age 53)Gen. Counsel, Chief Compliance Officer & Corp. Sec. Comp: $586.68kDr. Thomas B. Smith FAAFP (Age 61)M.D., Chief Medical Officer Comp: $570.06kMr. John Golubieski (Age 57)CFO & Chief Accounting Officer Mr. Joseph M. LockhartSr. VP of OperationsMr. Kevin OstranderSr. VP of Bus. Devel.Dr. Bill McCarbergMember of Scientific Advisory Board and Member of Arius Scientific Advisory BoardDr. Arthur G. Lipman PharmDMember of Scientific Advisory Board and Member of Arius Scientific Advisory BoardDr. Jeff KatzMember of Scientific Advisory Board and Member of Arius Scientific Advisory BoardMore ExecutivesKey CompetitorsNektar TherapeuticsNASDAQ:NKTROmerosNASDAQ:OMERImmunicNASDAQ:IMUXOsmotica PharmaceuticalsNASDAQ:OSMTPacira BioSciencesNASDAQ:PCRXView All Competitors BDSI Stock Analysis - Frequently Asked Questions How were BioDelivery Sciences International's earnings last quarter? BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced its quarterly earnings data on Tuesday, November, 2nd. The specialty pharmaceutical company reported $0.07 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.01. The specialty pharmaceutical company earned $41.09 million during the quarter, compared to analyst estimates of $42.05 million. BioDelivery Sciences International had a net margin of 50.90% and a trailing twelve-month return on equity of 21.25%. During the same quarter last year, the business posted $0.09 EPS. What other stocks do shareholders of BioDelivery Sciences International own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), JD.com (JD), Baidu (BIDU), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD) and Alibaba Group (BABA). This page (NASDAQ:BDSI) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioDelivery Sciences International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.